A M Romanic

Summary

Affiliation: SmithKline Beecham Pharmaceuticals
Country: USA

Publications

  1. ncbi Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients
    A M Romanic
    Department of Cardiovascular Pharmacology, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Am J Physiol Renal Physiol 281:F309-17. 2001
  2. ncbi Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 29:1020-30. 1998
  3. ncbi Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Circ Res 83:264-9. 1998
  4. ncbi Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Life Sci 68:799-814. 2001
  5. ncbi Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol
    T L Yue
    Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Circ Res 82:166-74. 1998
  6. ncbi Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Biochem Biophys Res Commun 271:138-43. 2000
  7. ncbi Application of in vivo and ex vivo magnetic resonance imaging for evaluation of tranilast on neointima formation following balloon angioplasty of the rat carotid artery
    E H Ohlstein
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, P O Box 1539, King of Prussia, Pa 19406 0939, USA
    Cardiovasc Res 47:759-68. 2000
  8. ncbi Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
    R S Ames
    Department of Molecular Biology, Smith Kline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 0939, USA
    Nature 401:282-6. 1999
  9. ncbi TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease
    T L Yue
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19046, USA
    J Biol Chem 274:1479-86. 1999
  10. pmc A mutation in the gene for type III procollagen (COL3A1) in a family with aortic aneurysms
    S Kontusaari
    Department of Biochemistry and Molecular Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
    J Clin Invest 86:1465-73. 1990

Detail Information

Publications10

  1. ncbi Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients
    A M Romanic
    Department of Cardiovascular Pharmacology, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Am J Physiol Renal Physiol 281:F309-17. 2001
    ..These results provide the first evidence of the expression of a MT-MMP in diabetes and suggest a novel role for MT5-MMP in the pathogenesis of renal tubular atrophy and end-stage renal disease...
  2. ncbi Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Stroke 29:1020-30. 1998
    ..The present study was designed to investigate the effects of MMP expression after stroke...
  3. ncbi Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Circ Res 83:264-9. 1998
    ....
  4. ncbi Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit
    A M Romanic
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Life Sci 68:799-814. 2001
    ..It is speculated that the net increase in proteolytic activity by myocytes is a contributing factor leading to myocyte misalignment and slippage. Additional studies with a MMP inhibitor would elucidate this hypothesis...
  5. ncbi Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol
    T L Yue
    Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
    Circ Res 82:166-74. 1998
    ..The former two actions represent novel and important mechanisms that may contribute to the cardioprotective effects of carvedilol...
  6. ncbi Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty
    X Wang
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    Biochem Biophys Res Commun 271:138-43. 2000
    ..The differential but concomitant expression of IL-1beta, IL-1ra, IL-1RI, and IL-1RII mRNAs after balloon angioplasty suggests that each of these IL-1 system components may play a distinct role in neointima formation...
  7. ncbi Application of in vivo and ex vivo magnetic resonance imaging for evaluation of tranilast on neointima formation following balloon angioplasty of the rat carotid artery
    E H Ohlstein
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, P O Box 1539, King of Prussia, Pa 19406 0939, USA
    Cardiovasc Res 47:759-68. 2000
    ..The utility of this study, using a reverse paradigm, is to investigate if agents successful in the clinic can demonstrate efficacy in this animal model primary screen as measured by MRI and histomorphometry...
  8. ncbi Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
    R S Ames
    Department of Molecular Biology, Smith Kline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406 0939, USA
    Nature 401:282-6. 1999
    ..Furthermore, as U-II immunoreactivity is also found within central nervous system and endocrine tissues, it may have additional activities...
  9. ncbi TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease
    T L Yue
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19046, USA
    J Biol Chem 274:1479-86. 1999
    ..These findings suggest that TL1 may act as an autocrine factor to induce apoptosis in endothelial cells via activation of multiple signaling pathways, including stress protein kinases as well as certain caspases...
  10. pmc A mutation in the gene for type III procollagen (COL3A1) in a family with aortic aneurysms
    S Kontusaari
    Department of Biochemistry and Molecular Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
    J Clin Invest 86:1465-73. 1990
    ..The results demonstrated that mutations in the type III procollagen gene can cause familial aortic aneurysms and that DNA tests for such mutations can identify individuals at risk for aneurysms...